This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
IKZF2 / Zinc finger protein Helios · IHC design guide
Design Immunohistochemistry for IKZF2
Plan paraffin-section IKZF2 IHC around the expected nuclear staining pattern (HPA tissue IHC). The catalog antibody has a human spleen IHC image at 5 μg/mL (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
IKZF2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in tissue (HPA tissue IHC) | |
| Staining pattern | General nuclear staining (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Bone marrow+2 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Nuclear positivity alone does not identify Tregs (HPA tissue IHC; UniProt) | |
| Regulation | Expressed in activated T cells (UniProt) | |
| Isoform / epitope | 8 isoforms; confirm epitope coverage (UniProt) |
Section 1
Recommended IKZF2 IHC & IF Protocols
The catalog antibody's IHC-P protocol is followed by published chromogenic IHC methods for IKZF2 in cutaneous T cell lymphoma and gastric cancer sections (PMC9472098; PMC7555661).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A05228); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-IKZF2, 5 μg/mL (datasheet A05228) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | IKZF2-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: General nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule; UniProt Q9UKS7: nuclear localisation).
Section 2
What Is the Expected IKZF2 Staining Pattern?
IKZF2 is a nuclear transcription factor with no transmembrane segment (UniProt Q9UKS7). In paraffin-section IHC, assess nuclear staining in the relevant cells: HPA reports high staining in several glandular, respiratory epithelial, endothelial, and stromal cell populations, alongside tissue-enhanced RNA expression in lymphoid tissue (HPA tissue IHC). HPA describes its tissue IHC profile as general nuclear expression, with Approved reliability and medium consistency between antibody staining and RNA data (HPA tissue IHC).
| Distinct nuclear chromogen in the expected cells, with interpretable counterstained nuclei. | This fits the general nuclear tissue IHC profile (HPA tissue IHC) and nuclear localization (UniProt Q9UKS7). Compare cells within the same section before scoring intensity; a positive nucleus supports localization but does not, by itself, identify a T-cell subtype or establish that every cell in that tissue expresses IKZF2. |
| Strong cytoplasm-only, membranous, or extracellular staining, with little nuclear signal. | A cytoplasm-only IHC pattern conflicts with the main nuclear expectation (UniProt Q9UKS7; HPA tissue IHC). Investigate background or nonspecific binding before calling it positive. HPA also reports additional cytosolic localization by ICC-IF, so limited cytosolic signal alone cannot settle whether a particular IHC stain is an artifact (HPA subcellular ICC-IF). |
| Prominent staining in a cell population reported as not detected by HPA. | For example, HPA reports no detection in bone-marrow hematopoietic cells and hippocampal glial cells (HPA tissue IHC). Unexpected staining warrants checks for nonspecific antibody binding or endogenous detection activity (general IHC practice). These observations concern the sampled cell categories; do not extend them to every cell or specimen from either tissue. |
| Chromogen spreads across cells, extracellular spaces, or much of the section without clear nuclear boundaries. | Diffuse deposition prevents a confident nuclear call against the HPA tissue IHC profile (HPA tissue IHC). Uneven reagent coverage, nonspecific binding, or endogenous enzyme activity can produce broad background in chromogenic IHC (general IHC practice). Compare a matched detection-only control and inspect whether the counterstain still separates individual nuclei. |
| No nuclear staining in a section chosen as an HPA high-staining example. | Absence of signal in the relevant cells of that section raises a technical or specimen question before a biological negative call. HPA reports high staining in adrenal-gland glandular cells and bronchial respiratory epithelial cells (HPA tissue IHC). Confirm that the expected cell population is present, then review the staining run with a suitable control (general IHC practice). |
💡Expected IKZF2 appearanceCall a positive result when identifiable target cells show clear nuclear staining, potentially high in the cell populations HPA scores high, while diffuse chromogen or dominant staining outside nuclei remains an unresolved false-positive pattern (HPA tissue IHC; UniProt Q9UKS7).
| Subcellular distribution | UniProt places IKZF2 in the nucleus and describes association with centromeric heterochromatin in T-cell nuclei (UniProt Q9UKS7). HPA describes nucleoplasm and nuclear bodies as approved main ICC-IF locations, with additional approved cytosol (HPA subcellular ICC-IF); use the tissue IHC profile for the primary slide call. |
| Choice of comparison tissue and cell population | HPA scores high staining in appendix glandular cells, colon endothelial cells, and endometrial stromal cells, among others (HPA tissue IHC). Match the scored cell type to the tissue entry: a tissue name alone does not make every cell in its section an expected positive. |
| Expression context | UniProt reports IKZF2 expression in developing thymocytes, activated T cells, regulatory T cells, and MAIT cells (UniProt Q9UKS7). HPA also reports high tissue IHC staining in several non-lymphoid cell categories and tissue-enhanced RNA expression in lymphoid tissue (HPA tissue IHC). Keep those evidence types distinct when selecting controls or interpreting mixed sections. |
| Antibody evidence | HPA lists HPA059142 as Approved for IHC and ICC, while its tissue IHC summary reports medium consistency with RNA expression (HPA antibodies; HPA tissue IHC). Treat this as support for the documented patterns, with the stated reliability limit; the supplied record does not establish an Enhanced IHC validation designation. |
| Isoforms and modifications | UniProt lists eight IKZF2 isoforms and annotated phosphoserines and an acetyllysine (UniProt Q9UKS7). The supplied evidence gives no antibody epitope or isoform coverage, so an IHC intensity difference cannot be assigned to a particular isoform or modification from these records alone. |
| Topology and processing | UniProt reports no transmembrane segment, signal peptide, or propeptide, and describes one chain spanning residues 1–526 (UniProt Q9UKS7). This supports assessing a nuclear protein rather than expecting a cell-surface outline; the supplied record does not support a shedding-based explanation for extracellular chromogen. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive cells are present, but their nuclei are unstained. | The result may reflect the staining run or specimen; the high-staining HPA entry alone cannot identify the failure step (HPA tissue IHC). | Check a suitable positive control and the detection-only control, then review antigen retrieval and reagent performance using the established paraffin IHC workflow (general IHC practice). |
| The apparent positive result is mainly cytoplasmic. | It does not match the general nuclear tissue IHC profile (HPA tissue IHC), although additional cytosol is reported in ICC-IF (HPA subcellular ICC-IF). | Check for nuclear signal in the same cells and compare matched controls; report the compartment actually observed rather than assigning a nuclear positive score (general IHC practice). |
| Unexpected cells stain strongly beside plausible positive cells. | Nonspecific binding or endogenous detection activity may imitate a positive chromogenic signal (general IHC practice); HPA cell-level patterns vary within and across tissues (HPA tissue IHC). | Identify the stained cell population, compare it with the matching HPA entry, and inspect a detection-only control before attributing the signal to IKZF2 (general IHC practice). |
| Background obscures nuclear boundaries across the section. | Diffuse chromogen makes comparison with the HPA general nuclear pattern unreliable (HPA tissue IHC); nonspecific binding or endogenous enzyme activity are possible causes (general IHC practice). | Review blocking, wash steps, detection chemistry, and counterstain visibility; use a matched detection-only control to locate background introduced by the staining workflow (general IHC practice). |
| Two specimens give different proportions of stained nuclei. | A change in sampled cell populations could alter the apparent result; HPA assigns levels to specified cells, and reports medium consistency between tissue staining and RNA data (HPA tissue IHC). | Score the same identifiable cell population in each specimen and record nuclear intensity and the fraction of stained cells separately (general IHC practice). Do not infer an isoform or modification change from intensity alone (UniProt Q9UKS7). |
| IF/ICC Q&A: Should cytosolic fluorescence override a nuclear paraffin IHC interpretation? | HPA approves nucleoplasm and nuclear bodies as main ICC-IF locations and cytosol as an additional location (HPA subcellular ICC-IF); it describes general nuclear expression in tissue IHC (HPA tissue IHC). | Interpret each preparation against its own documented pattern and controls. For paraffin IHC, base the positive call on identifiable nuclear staining in the relevant cells (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing IKZF2 staining
A05228 · IHCImmunohistochemistry of IKZF2 in human spleen tissue with IKZF2 antibody at 5 μg/mL.
A05228 · IFImmunofluorescence of IKZF2 in human spleen tissue with IKZF2 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000030419-IKZF2/tissue/cerebral+cortex#imid_16388919
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000030419-IKZF2/tissue/colon#imid_16388853
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000030419-IKZF2/tissue/liver#imid_16388846
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000030419-IKZF2/tissue/kidney#imid_16388847
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA059142; green = IKZF2, blue = nucleus, red = microtubules.
HPA · ICC-IF HeLaHuman Protein Atlas immunofluorescence, HeLa, antibody HPA059142; green = IKZF2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for IKZF2 IHC & IF
🧪Run breast first: glandular cells should show IKZF2 staining (HPA: High in breast glandular cells). Use cerebral cortex endothelial cells as the negative comparator (HPA: Not detected); on the breast slide, cells outside the glandular compartment are candidate internal negatives and should lack nuclear signal above background once their status is validated (HPA: High in glandular cells; UniProt Q9UKS7: nuclear localization).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Bone marrow (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show IKZF2 in HeLa, RT-4, U2OS, with annotated localisation: Nucleoplasm (approved), Nuclear bodies (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control; a control immunoglobulin matched to the primary antibody’s host species, isotype and monoclonal or polyclonal format; and, if available, IKZF2 knockout material as a biological specificity control (standard IHC practice). For chromogenic HRP detection, quench endogenous peroxidase and inspect breast gland lumens for deposited chromogen before scoring nuclei (standard IHC practice; UniProt Q9UKS7: nuclear localization).
⚠️Feasibility: The A05228 spleen IHC caption reports 5 μg/mL but does not state a fixative; a target-specific fixation window and retrieval requirement are unreported in the supplied evidence (A05228 tissue-IHC caption). Retrieval conditions therefore need empirical optimization for paraffin sections, and the supplied evidence does not establish that frozen sections or IF are easier (standard IHC practice; HPA: ICC-IF subcellular images). In breast, score nuclear staining in glandular cells and exclude luminal chromogen deposits from that score (HPA: High in breast glandular cells; UniProt Q9UKS7: nuclear localization; standard IHC practice).
HPA tissue IHC evidence for IKZF2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
Section 3
Advanced IKZF2 IHC Tips
Troubleshoot IKZF2 staining by checking retrieval, nuclear signal, controls, and cell-specific scoring before interpreting chromogenic IHC.
How should I adjust retrieval when IKZF2 nuclear staining is weak?
Start with Tris-EDTA at pH 9.0, heated to 95–98 °C for 20 min (page retrieval specification). Assess retrieval by the clarity of nuclear staining, since IKZF2 is predominantly nuclear (UniProt Q9UKS7 localization; HPA subcellular). If staining remains weak, verify the measured buffer pH and bath temperature, then compare a longer retrieval run or citrate at pH 6.0 on adjacent sections as fallbacks (standard IHC practice). Keep antibody concentration and chromogen development constant during that comparison, and reject conditions that damage tissue or spread signal beyond nuclei (standard IHC practice).
Can fixation explain weak IKZF2 staining in paraffin sections?
The A05228 spleen IHC caption reports 5 µg/mL antibody but does not state the fixative, so IKZF2-specific fixation sensitivity is unknown (selected tissue-IHC caption). Record each specimen’s fixation type, duration, and processing history before comparing staining intensity (standard IHC practice). If signal differs between specimens, compare sections with documented processing histories while keeping Tris-EDTA pH 9.0, 95–98 °C, 20 min retrieval and detection conditions constant (page retrieval specification; standard IHC practice). Examine nuclear morphology and section edges for processing damage; IKZF2 localization and phosphosites alone cannot establish a fixation effect (standard IHC practice; UniProt Q9UKS7).
What staining compartment should count as an IKZF2-positive cell?
Score a cell as positive primarily when its nucleus has convincing chromogenic signal, because IKZF2 is nuclear and can associate with centromeric heterochromatin in T-cell nuclei (UniProt Q9UKS7 localization). Nucleoplasmic and nuclear-body staining are also reported, with additional cytosolic localization in cell imaging (HPA subcellular). Compare staining with a nuclear counterstain and review individual cells at high magnification before assigning positivity (standard IHC practice). If cytoplasmic color dominates while nuclei are blank, check the no-primary control and detection conditions before treating that pattern as IKZF2 expression (standard IHC practice; UniProt Q9UKS7 localization).
Can this IHC stain distinguish IKZF2 isoforms or modified protein?
The record lists 8 IKZF2 isoforms, but the supplied antibody evidence gives no epitope map or isoform-reactivity data (UniProt Q9UKS7 isoforms; selected tissue-IHC caption). Therefore, chromogenic staining cannot be assigned to a particular isoform from these inputs alone (UniProt Q9UKS7 isoforms; standard IHC interpretation). IKZF2 also has annotated phosphoserines at residues 56, 78, and 79 and an acetyllysine at 288; their effects on this antibody are unknown (UniProt Q9UKS7 modified residues). For an isoform or modification claim, obtain epitope documentation and compare appropriate validated controls under matched retrieval and detection conditions (standard IHC practice).
How should I assess IKZF2 in a multiplex IF follow-up?
Use this as an IF design check alongside the chromogenic IHC result: IKZF2 is nuclear and is expressed in regulatory and other T-cell populations (UniProt Q9UKS7 localization and tissue specificity). Pair nuclear IKZF2 with a separately validated T-cell or regulatory T-cell marker, and inspect cell-by-cell overlap rather than inferring identity from proximity (standard IF practice). Choose separated fluorophores and place the weaker signal in a channel with low tissue autofluorescence, using single-color and unstained controls to assess bleed-through (standard IF practice). Because IKZF2 has no transmembrane segment, use controlled permeabilisation to access its intracellular epitope, then verify nuclear morphology and localization (UniProt Q9UKS7 topology; standard IF practice).
How can I separate IKZF2 signal from chromogenic background?
First inspect no-primary and detection-only sections for nonspecific color, and include a peroxidase block when using an enzyme-based DAB workflow (standard IHC practice). Compare nuclear staining with diffuse cytoplasmic deposits, precipitate, and edge-darkening at the same magnification (standard IHC practice; UniProt Q9UKS7 localization). If background obscures nuclei, optimize blocking, washes, primary-antibody exposure, and chromogen development one variable at a time while retaining the specified pH 9.0 retrieval (standard IHC practice; page retrieval specification). Do not classify every stained non-T cell as background: HPA reports nuclear expression and staining in several glandular and endothelial cell populations (HPA tissue IHC).
What is a defensible way to quantify IKZF2 IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue compartment and eligible cell population before scoring, then count only cells with interpretable nuclei and record exclusions for damaged areas (standard IHC practice; UniProt Q9UKS7 localization). Report the percentage of nuclear-positive cells and, if intensity matters, an H-score based on predefined nuclear intensity categories (standard IHC practice). For spatial comparisons, report positive-cell density per mm² of evaluable tissue and normalize counts to the number of eligible cells or assessed area, as appropriate (standard IHC practice). Keep retrieval, imaging, thresholds, and chromogen development consistent across sections, and report cell-type-specific results because HPA describes broad nuclear staining (standard IHC practice; HPA tissue IHC).
When is apparent IKZF2 positivity likely to be artefactual?
Treat crisp nuclear staining in morphologically intact cells as more persuasive than diffuse cytoplasmic color, given IKZF2’s nuclear localization (UniProt Q9UKS7 localization; standard IHC practice). Check whether apparent positives cluster at section edges, in necrotic areas, or where the no-primary section shows endogenous enzyme signal (standard IHC practice). Interpret cell identity carefully: IKZF2 is expressed in several T-cell populations, while HPA also reports nuclear staining in other cell types (UniProt Q9UKS7 tissue specificity; HPA tissue IHC). HPA rates its tissue IHC profile Approved with medium staining-to-RNA consistency, so reconcile unexpected compartments or cell populations with morphology and controls before making a biological claim (HPA tissue IHC; standard IHC practice).
Boster reagents
Best IKZF2 / Zinc finger protein Helios IHC Antibodies
The catalog antibody has IHC and IF images from human spleen (catalog image captions); Human, Mouse and Rat reactivity is listed (catalog: A05228 reactivity).
Real IHC data
Anti-Zinc finger protein Helios IKZF2 Antibody
Cat # A05228
A05228 is listed for IHC-P and IF (catalog: A05228 applications). Its images show human spleen IHC at 5 μg/mL and IF at 20 μg/mL (catalog: A05228 image captions).
Which to pick: For paraffin-section IHC, choose A05228: IHC-P is listed, and its own IHC caption shows human spleen at 5 μg/mL (catalog: A05228 applications and IHC image caption); the fixative is unreported (catalog: A05228 IHC image caption). For IF, A05228 has a human spleen image at 20 μg/mL (catalog: A05228 IF image caption); ICC is not listed (catalog: A05228 applications). For Mouse or Rat samples, A05228 lists reactivity in both species (catalog: A05228 reactivity), while the supplied IHC and IF images show Human tissue (catalog: A05228 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q9UKS7 (IKZF2_HUMAN, Zinc finger protein Helios).
- Human Protein Atlas. IKZF2 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. IKZF2 subcellular location (ICC-IF): Mainly localized to the nucleoplasm and nuclear bodies. In addition localized to the cytosol..
- Human Protein Atlas. IKZF2 antibody validation summary (1 antibodies).
- High Expression of IKZF2 in Malignant T Cells Promotes Disease Progression in Cutaneous T Cell Lymphoma. Acta dermato-venereologica 2021 — PMC9472098.
- Helios Expression in Tumor-Infiltrating Lymphocytes Correlates with Overall Survival of Advanced Gastric Cancer Patients. Life (Basel, Switzerland) 2020 — PMC7555661.
- Helios is a key transcriptional regulator of outer hair cell maturation. Nature 2018 — PMC6542691.
- Single-cell transcriptome reveals the reprogramming of immune microenvironment during the transition from MASH to HCC. Molecular cancer 2025 — PMC12153197.
- PubMed PMID:10541817 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:10978333 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for IKZF2 (Zinc finger protein Helios). Expected localisation Nuclear staining in tissue (HPA tissue IHC). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A05228 at 5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Bone marrow. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A05228); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-IKZF2, 5 μg/mL (datasheet A05228); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Nuclear positivity alone does not identify Tregs (HPA tissue IHC; UniProt); Isoform / epitope: 8 isoforms; confirm epitope coverage (UniProt); Regulation: Expressed in activated T cells (UniProt). Evidence: UniProt Q9UKS7, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the nucleoplasm and nuclear bodies. In addition…, Datasheet A05228, PMC9472098, PMC7555661. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/IKZF2/immunohistochemistry-ihc-guide.